Travere Therapeutics, Inc. (TVTX): Revenue
$490.73M
Year ended 2025-12-31
$591.33M
Trailing 12 months to 2026-06-30
+64.9%
3-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $490.73M | +110.5% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $233.18M | +60.5% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $145.24M | +32.7% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $109.46M | -17.0% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $131.84M | n/c | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $198.32M | +13.1% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $175.34M | +6.8% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $164.25M | +6.0% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $154.94M | +16.0% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $133.59M | n/a | 2019-02-26, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.73M | +110.5% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $480.14M | +5.7% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $502.08M | +126.3% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $521.31M | +54.7% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $457.18M | +15.0% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $548.51M | -13.0% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $564.17M | +17.0% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $411.33M | +14.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $407.32M | +22.1% |
Compare TVTX, NATR, BBIO, MIRM side by side · Screen every company in Pharmaceutical Preparations ↗